1,675 results match your criteria Pulmonary Pharmacology and Therapeutics[Journal]


Precision-cut lung slices from bleomycin treated animals as a model for testing potential therapies for idiopathic pulmonary fibrosis.

Pulm Pharmacol Ther 2019 Feb 15. Epub 2019 Feb 15.

Fidelta Ltd., Prilaz baruna Filipovića 29, 10000, Zagreb, Croatia.

Idiopathic pulmonary fibrosis (IPF) is a complex lung disease with incompletely understood pathophysiology. Effectiveness of available medicines is limited and the need for new and improved therapies remains. Due to complexity of the disease, it is difficult to develop predictable in vitro models. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2019.02.005DOI Listing
February 2019

Cough in exercise and athletes.

Pulm Pharmacol Ther 2019 Feb 13. Epub 2019 Feb 13.

Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Canada.

In the general population, particularly in individuals with asthma, cough is a common symptom, often reported after exertion, although regular exercise may be associated with a reduction in the prevalence of cough. In athletes, exercise-induced cough is also a particularly frequent symptom. The main etiologies of cough in athletes are somewhat similar to non-athletes, including asthma/airway hyperresponsiveness, upper airways disorders such as allergic or non-allergic rhinitis, and exercise-induced laryngeal obstruction, although these conditions are more frequently observed in athletes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2019.02.003DOI Listing
February 2019
1 Read

Heterogeneity of cough neurobiology: Clinical implications.

Pulm Pharmacol Ther 2019 Feb 11. Epub 2019 Feb 11.

Monash Biomedicine Discovery Institute and Department of Medical Imaging and Radiation Sciences, Monash University, Clayton, Vic, 3800, Australia.

Cough is an important protective mechanism for clearing the airways but becomes a troublesome, and often difficult to treat, symptom in respiratory disease. Although cough can be produced as a reflex in response to the presence of irritants within the airways, emerging research demonstrates an unappreciated complexity in the peripheral and central neural systems that regulate cough. This complexity includes multiple primary sensory neurons that can induce or facilitate reflex coughing, different ascending central circuits in the brain that contribute to cough sensory discrimination and the perception of the urge-to-cough, and several descending brain systems for inducing, facilitating and inhibiting cough responses. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2019.02.002DOI Listing
February 2019

Inhalable dry powder prepared from folic acid-conjugated docetaxel liposomes alters pharmacodynamic and pharmacokinetic properties relevant to lung cancer chemotherapy.

Pulm Pharmacol Ther 2019 Feb 7. Epub 2019 Feb 7.

Clinical Pharmacokinetics Laboratory, School of Basic Medical and Clinical Pharmacy, China Pharmaceutical University, Nanjing, 211198, People's Republic of China. Electronic address:

Pulmonary delivery of anti-cancer drugs in the form of nanoparticulate dry powders is considered a promising modality for treating lung cancer. However, it is not known whether the pharmacodynamics and pharmacokinetics of nano-preparations are altered after co-spray drying. In this study, we compared the physicochemical property, anti-cancer activity, tumor targeting and pharmacokinetic behavior of docetaxel-loaded folic acid-conjugated liposomes (LPs-DTX-FA) with those of dry powder prepared by co-spray-drying LPs-DTX-FA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2019.02.001DOI Listing
February 2019
1 Read

Cough in pulmonary tuberculosis: Existing knowledge and general insights.

Pulm Pharmacol Ther 2019 Feb 1. Epub 2019 Feb 1.

Department of Respiratory Medicine, Imperial College Healthcare NHS Trust, London, UK. Electronic address:

Cough is a prominent symptom of pulmonary tuberculosis (TB), one of the oldest and most prevalent infectious diseases. Coughing probably has a pivotal role in transmission of the causative organism Mycobacterium tuberculosis. Despite this, little research to date has addressed this subject. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2019.01.008DOI Listing
February 2019
3 Reads

SUMOylation of Vps34 by SUMO1 promotes phenotypic switching of vascular smooth muscle cells by activating autophagy in pulmonary arterial hypertension.

Pulm Pharmacol Ther 2019 Jan 28. Epub 2019 Jan 28.

Key Laboratory of Molecular Biophysics of the Ministry of Education, College of Life Science and Technology and Center for Human Genome Research, Huazhong University of Science and Technology, Wuhan, PR China; Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, 44195, USA; Department of Molecular Medicine, CCLCM of Case Western Reserve University, Cleveland, OH, 44195, USA; Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, 44106, USA. Electronic address:

Introduction: Pulmonary arterial hypertension (PAH) is a life-threatening disease without effective therapies. PAH is associated with a progressive increase in pulmonary vascular resistance and irreversible pulmonary vascular remodeling. SUMO1 (small ubiquitin-related modifier 1) can bind to target proteins and lead to protein SUMOylation, an important post-translational modification with a key role in many diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2019.01.007DOI Listing
January 2019

Adrenomedullin mediates pro-angiogenic and pro-inflammatory cytokines in asthma and COPD.

Pulm Pharmacol Ther 2019 Jan 25. Epub 2019 Jan 25.

Clinic of Pulmonary Medicine and Respiratory Cell Research, University Hospital, Department of Biomedicine, University of Basel, Basel, Switzerland. Electronic address:

Purpose: Adrenomedullin (AM) is a pluripotent peptide hormone with contradictory effects in human health and disease. In chronic inflammatory lung diseases, such as asthma and COPD, AM has been shown to inhibit inflammation and cell proliferation. In the present study, we aimed to investigate the effect of AM on pro-angiogenic and pro-inflammatory cytokines in asthma and COPD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2019.01.006DOI Listing
January 2019
2.937 Impact Factor

Limitations of the results from randomized clinical trials involving intravenous and nebulised magnesium sulphate in adults with severe acute asthma.

Pulm Pharmacol Ther 2019 Jan 17. Epub 2019 Jan 17.

Department of Pulmonology, University Hospital Centre Zagreb, Zagreb, Croatia. Electronic address:

The role of intravenous (IV) or nebulised magnesium sulphate (MgSO) in the treatment of severe acute asthma in adults is unclear. A controversy exists regarding its efficacy. In children MgSO has a more evident clinical effect, but the child population has not been considered in this work. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2019.01.005DOI Listing
January 2019
2 Reads

Vitamin D prevents experimental lung fibrosis and predicts survival in patients with idiopathic pulmonary fibrosis.

Pulm Pharmacol Ther 2019 Jan 16. Epub 2019 Jan 16.

1st Academic Department of Respiratory Medicine, Medical School, National and Kapodistrian University of Athens, Hospital for Diseases of the Chest, "Sotiria", Athens, Greece; Biomedical Sciences Research Center, "Alexander Fleming", Division of Immunology, Athens, Greece. Electronic address:

Background: Vitamin D (VitD) is a steroid hormone with cytoprotective and anti-inflammatory properties. Epidemiological studies have suggested a link between VitD deficiency and risk of development of chronic lung diseases. Its role in lung fibrosis is largely unknown. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10945539183023
Publisher Site
http://dx.doi.org/10.1016/j.pupt.2019.01.003DOI Listing
January 2019
12 Reads

The anti-proliferative effects of adiponectin on human lung adenocarcinoma A549 cells and oxidative stress involvement.

Pulm Pharmacol Ther 2019 Jan 14. Epub 2019 Jan 14.

Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", Napoli, Italy.

Adiponectin (Acrp30) plays an important role in energy metabolism and inflammation. Recently, in vivo serum Acrp30 levels have been reported to be correlated to risk of developing several types of cancers such as lung cancer, and in vitro studies have demonstrated a role for Acrp30 in the control of cell proliferation and survival. However, the molecular effects of Acrp30 on lung cancer have not yet been clearly defined. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2019.01.004DOI Listing
January 2019
3 Reads

Alteplase and DNase for the treatment of pleural empyema in rats.

Pulm Pharmacol Ther 2019 Jan 12. Epub 2019 Jan 12.

Engenheiro Biomedical Engineer, Clinicas Hospital of Porto Alegre, Brazil.

Background And Objectives: Adjunctive intrapleural fibrinolytic is an option to treat empyema at fibrinopurulent stage, but there is controversy about which should be use. Our objective is to evaluate the action of alteplase and/or desoxyribonuclease at physical and chemical properties in vitro pus derived from an experimental induced empyema in rats.

Methods: Streptococcus pneumoniae was introduced into the pleural cavity by thoracentesis through pleural pressure monitor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2019.01.001DOI Listing
January 2019
6 Reads

Penehyclidine effects the angiogenic potential of pulmonary microvascular endothelial cells.

Pulm Pharmacol Ther 2019 Jan 11. Epub 2019 Jan 11.

Department of Anesthesiology and Perioperative Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address:

The present study sought to determine the pharmacological effects of penehyclidine, an anticholinergic agent, on the angiogenic capacity of pulmonary microvascular endothelial cells (PMVECs). In vitro Matrigel network formation assay, cell proliferation assay, cell-matrix adhesion assay, and wound-healing assay were performed in PMVECs with or without exposure to penehyclidine or, in some cases, glycopyrrolate or acetylcholine, over a concentration range. In addition, the phosphorylation state of Akt and ERK, as well as the endogenous level of mTOR and RICTOR were examined in PMVECs by Western blot following the cells exposure to penehyclidine or, for some proteins, glycopyrrolate or acetylcholine. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2019.01.002DOI Listing
January 2019
1 Read

GYY4137 attenuates LPS-induced acute lung injury via heme oxygenase-1 modulation.

Pulm Pharmacol Ther 2019 Feb 31;54:77-86. Epub 2018 Dec 31.

Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. Electronic address:

GYY4137, a slow-releasing hydrogen sulfide (HS) donor, has been reported to exert anti-inflammatory activity and protect against sepsis. Heme oxygenase-1 (HO-1) is an important anti-inflammatory heat shock protein and plays a similar effect on sepsis. This study investigated the role of GYY4137 in acute lung injury (ALI) via HO-1 regulation. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10945539183009
Publisher Site
http://dx.doi.org/10.1016/j.pupt.2018.12.004DOI Listing
February 2019
3 Reads

Analysis of the drop-out rate in patients receiving mepolizumab for severe asthma in real life.

Pulm Pharmacol Ther 2019 Feb 29;54:87-89. Epub 2018 Dec 29.

Allergy & Respiratory Diseases, University of Genoa, Genoa, Italy.

Mepolizumab (anti IL-5, monoclonal antibody) is commercially available in Italy since more than one year for the treatment of severe hypereosinophilic asthma. Its efficacy and safety were evaluated in several regulatory trials. The characteristics of this drug in real life began to be assessed only recently. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2018.12.003DOI Listing
February 2019
2 Reads

Efficacy and safety of a novel nitric oxide generator for the treatment of neonatal pulmonary hypertension: Experimental and clinical studies.

Pulm Pharmacol Ther 2019 Feb 8;54:68-76. Epub 2018 Dec 8.

Department of Neonatology, University Hospital, Montevideo, 11600, Uruguay.

Persistent pulmonary hypertension of the newborn (PPHN) is a complex pathology resulting from a failure of the post-natal reduction in pulmonary vascular resistance leading to hypoxemia. The standard therapy is inhaled Nitric Oxide (NO) improving oxygenation but its availability is limited, especially in hospitals with restricted financial resources. We evaluated the efficacy and safety of a new device generating NO (TAS + PLUS), in three experimental piglet models of pulmonary hypertension (PH), and we later tested its application in a pilot study of newborn patients suffering from PPHN. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2018.12.002DOI Listing
February 2019
2 Reads

Arbutin attenuates LPS-induced lung injury via Sirt1/ Nrf2/ NF-κBp65 pathway.

Pulm Pharmacol Ther 2019 Feb 6;54:53-59. Epub 2018 Dec 6.

The Third Affiliated Hospital of Soochow University, Changzhou, 213000, China; Department of Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 200433, China. Electronic address:

The main goal of this study was to evaluate the effects of arbutin (AR) on lipopolysaccharide (LPS)-induced lung injury. A lung injury rat model was established by intravenous LPS administration. We found that levels of inflammatory cytokines, including tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6) in both serum and lung tissue were significant increased after LPS challenge. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2018.12.001DOI Listing
February 2019
2 Reads

The effect of erdosteine on airway defence mechanisms and inflammatory cytokines in the settings of allergic inflammation.

Pulm Pharmacol Ther 2019 Feb 28;54:60-67. Epub 2018 Nov 28.

Comenius University in Bratislava, Jessenius Faculty of Medicine in Martin, Department of Pharmacology, Martin, Slovakia.

Introduction: Mucoactive agent, erdosteine, besides mucolytic activity, is characterized by many other pharmacodynamic properties which could be beneficial in the management of inflammatory conditions.

Background: Using guinea pig experimental model of allergic inflammation, we evaluated the ability of erdosteine to modulate airway defence mechanisms and inflammation after 10 days (10 mg/kg/day) administration.

Methods: In vivo changes in specific airway resistance and amplitude of tracheal contraction were estimated to evaluate the bronchodilatory effect. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2018.11.006DOI Listing
February 2019
2 Reads

Effect of mesenchymal stromal (stem) cell (MSC) transplantation in asthmatic animal models: A systematic review and meta-analysis.

Authors:
Li-Bo Zhang Min He

Pulm Pharmacol Ther 2019 Feb 26;54:39-52. Epub 2018 Nov 26.

Department of Respiratory Medicine, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, China. Electronic address:

Background: Over the years, mesenchymal stromal (stem) cells (MSCs) have been pre-clinically applied in the treatment of variety kinds of diseases including asthma and chronic lung diseases. Aim of the current study was to systematically review and to conduct meta-analysis on the published studies of MSC treatment in asthma animal models.

Methods: Publications on the MSC and asthma treatment was thoroughly searched in the electronic databases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2018.11.007DOI Listing
February 2019
2 Reads

Attenuation of pulmonary fibrosis in type I collagen-targeted reporter mice with ALK-5 inhibitors.

Pulm Pharmacol Ther 2019 Feb 15;54:31-38. Epub 2018 Nov 15.

End-Organ Disease Laboratories, Daiichi Sankyo Co., Ltd, 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan.

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease, and consequently, effective antifibrotic drugs are strongly desired. Although we have previously reported a validated Col1a1-Luc Tg rat model for fibrosis, there are only a few mouse models that enable the evaluation of fibrosis in a short time period and with high sensitivity. Therefore, we generated a Col1a1-internal ribosome entry site (IRES)-Luc knock-in (KI) mouse in which the IRES-luciferase gene construct was inserted into the 3'-UTR of the type I collagen alpha 1 gene (Col1a1). Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10945539183009
Publisher Site
http://dx.doi.org/10.1016/j.pupt.2018.11.005DOI Listing
February 2019
10 Reads

Insight into pulmonary drug delivery: Mechanism of drug deposition to device characterization and regulatory requirements.

Pulm Pharmacol Ther 2019 Feb 14;54:1-21. Epub 2018 Nov 14.

Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER-HYD), Balanagar, Telangana, 500037, India. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10945539183018
Publisher Site
http://dx.doi.org/10.1016/j.pupt.2018.11.004DOI Listing
February 2019
8 Reads

Prevalence of Arnold nerve reflex in subjects with and without chronic cough: Relevance to Cough Hypersensitivity Syndrome.

Pulm Pharmacol Ther 2019 Feb 13;54:22-24. Epub 2018 Nov 13.

Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, USA.

Introduction: Cough is induced by stimulation of structures innervated by the vagus nerve, including the upper and lower airways and distal esophagus. The Arnold nerve reflex describes cough resulting from stimulation of the external auditory canal, which is innervated by the auricular branch of the vagus. We have recently reported the increased prevalence of this reflex in adults, but not children, with chronic cough, relative to healthy adult and pediatric subjects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2018.11.003DOI Listing
February 2019
2 Reads

Omalizumab lowers asthma exacerbations, oral corticosteroid intake and blood eosinophils: Results of a 5-YEAR single-centre observational study.

Pulm Pharmacol Ther 2019 Feb 7;54:25-30. Epub 2018 Nov 7.

Department of Medical and Surgical Sciences, Section of Respiratory Diseases, University "Magna Græcia" of Catanzaro, Italy. Electronic address:

Omalizumab is a humanized monoclonal antibody which binds to human immunoglobulins E (IgE), thus preventing their interactions with both high affinity and low affinity IgE receptors. Therefore, omalizumab is currently recommended for add-on biological therapy of uncontrolled allergic asthma, mainly characterized by type 2 airway eosinophilic inflammation. Because omalizumab has been the first, and for a long time the only available monoclonal antibody for add-on treatment of type 2 asthma, some long-term studies have been published which provide a clear evidence of the therapeutic effectiveness of the anti-IgE pharmacological strategy. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10945539183024
Publisher Site
http://dx.doi.org/10.1016/j.pupt.2018.11.002DOI Listing
February 2019
10 Reads

Varenicline for long term smoking cessation in patients with COPD.

Pulm Pharmacol Ther 2018 Dec 3;53:116-120. Epub 2018 Nov 3.

Department of Experimental Medicine and Surgery, Chair of Respiratory Medicine, University of Rome 'Tor Vergata', Via Montpellier, 100133, Rome, Italy.

Background: Quitting smoking is key for patients with Chronic Obstructive Pulmonary Disease (COPD). Standard recommendations for quitting smoking are implemented for COPD as well. Varenicline Tartrate (VT) is the most effective drug to help quit smoking, but few studies have analysed its effectiveness. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10945539183004
Publisher Site
http://dx.doi.org/10.1016/j.pupt.2018.11.001DOI Listing
December 2018
18 Reads

Antifibrotic effects of a novel pirfenidone derivative in vitro and in vivo.

Pulm Pharmacol Ther 2018 Dec 28;53:100-106. Epub 2018 Oct 28.

Institute of Materia Medica, Zhejiang Academy of Medical Sciences, Hangzhou, 310013, China. Electronic address:

Background: Idiopathic pulmonary fibrosis is a lethal fibrosing interstitial pneumonia characterized by progressive worsening of dyspnea and lung function with poor prognosis. Since pirfenidone was approved for IPF treatment, the search for more effective candidates has been greatly intensified.

Methods: In this study, the antifibrotic effects and mechanisms of compound PBD-617, the ideal candidate discovered in our previous work, were investigated on transforming growth factor-β1 (TGF-β1)-induced human embryonic lung fibroblasts (HELF) and on bleomycin (BLM)-induced pulmonary fibrotic rats. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2018.10.006DOI Listing
December 2018
3 Reads
2.937 Impact Factor

Inhaled calcium salts inhibit tobacco smoke-induced inflammation by modulating expression of chemokines and cytokines.

Pulm Pharmacol Ther 2018 Dec 22;53:86-99. Epub 2018 Oct 22.

Pulmatrix Inc., 99 Hayden Ave, Suite 390, Lexington, MA 02421, USA. Electronic address:

Tobacco smoke-induced lung inflammation in patients with chronic obstructive pulmonary disease (COPD) worsens with disease progression and acute exacerbations caused by respiratory infections. Chronic therapies to manage COPD center on bronchodilators to improve lung function and inhaled corticosteroids (ICS) to help reduce the risk of exacerbations. Novel therapies are needed that reduce the underlying inflammation associated with COPD and the inflammation resulting from respiratory infections that worsen disease. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10945539183009
Publisher Site
http://dx.doi.org/10.1016/j.pupt.2018.10.004DOI Listing
December 2018
13 Reads

Erdosteine: Drug exhibiting polypharmacy for the treatment of respiratory diseases.

Pulm Pharmacol Ther 2018 Dec 21;53:80-85. Epub 2018 Oct 21.

Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.

Mucoactive drugs are commonly used in the treatment of acute respiratory tract diseases, such as lower and acute respiratory infection and chronic bronchitis (CB) or chronic obstructive pulmonary disease (COPD) in which an increased mucus secretion is one of main clinical features. Indeed these drugs are designed to promote secretion clearance and to specifically alter the viscoelastic properties of mucus, restoring an effective mucociliary clearance and reducing broncho-obstructive symptoms. In association with mucolytics, these patients frequently also receive antibiotics to reduce the bacterial load, thus decreasing the release of infectious and pro-inflammatory products. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10945539183018
Publisher Site
http://dx.doi.org/10.1016/j.pupt.2018.10.005DOI Listing
December 2018
17 Reads

Aspirin use and racial differences in Non-Small cell lung cancer survival: What is the plot?

Pulm Pharmacol Ther 2018 Dec 11;53:79. Epub 2018 Oct 11.

Division of Pediatrics and Neonatology, Moscati Hospital, Via A. Gramsci, 81031, Aversa, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2018.10.002DOI Listing
December 2018
1 Read

Oncogenic activity of insulin in the development of NSCLC: What is there behind the scenes?

Pulm Pharmacol Ther 2018 Dec 11;53:78. Epub 2018 Oct 11.

Division of Pediatrics and Neonatology, Moscati Hospital, Via A. Gramsci, 81031, Aversa, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2018.10.003DOI Listing
December 2018
1 Read

Salvianolic acid B as an anti-emphysema agent I: In vitro stimulation of lung cell proliferation and migration, and protection against lung cell death, and in vivo lung STAT3 activation and VEGF elevation.

Pulm Pharmacol Ther 2018 Dec 4;53:107-115. Epub 2018 Oct 4.

Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University, 410 N. 12th Street, P. O. Box 980533, Richmond, VA, 23298, USA. Electronic address:

Emphysema causes progressive and life-threatening alveolar structural destruction/loss, yet remains irreversible and incurable to date. Impaired vascular endothelial growth factor (VEGF) signaling has been proposed as a new pathogenic mechanism, and if so, VEGF recovery may enable reversal of emphysema. Thus, we hypothesized that salvianolic acid B (Sal-B), a polyphenol in traditional Chinese herbal danshen, is an alveolar structural recovery agent for emphysema by virtue of VEGF stimulation/elevation via activation of Janus kinase 2 (JAK2) and signal transducer and activator of transcription 3 (STAT3), as stimulating lung cell proliferation and migration, and protecting against lung cell death. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10945539183012
Publisher Site
http://dx.doi.org/10.1016/j.pupt.2018.10.001DOI Listing
December 2018
8 Reads

Building reliable evidence from real-world data: Needs, methods, cautiousness and recommendations.

Pulm Pharmacol Ther 2018 Dec 22;53:61-67. Epub 2018 Sep 22.

Center of Healthcare Research & Pharmacoepidemiology, University of Milano-Bicocca, Italy. Electronic address:

National healthcare systems of advanced countries, including Italy, widely agree on the approach whereby public healthcare decisions should be driven by available evidence on effectiveness and safety of therapeutics. It is equally accepted that randomized controlled clinical trials (RCTs), although universally recognised as the most robust "evidence generators", are insufficient for guiding the decision-making process since they are intrinsically unsuited to capture the impact of treatments in routine clinical practice. The complexity of treatments, as well as the demographic and clinical heterogeneity of patients receiving the treatments, and the long period of many treatments, explain the gap between the evidence generated in the controlled, but artificial, setting of RCTs and their current impact in the real world. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2018.09.009DOI Listing
December 2018
2 Reads

Andrographolide prevented toluene diisocyanate-induced occupational asthma and aberrant airway E-cadherin distribution via p38 MAPK-dependent Nrf2 induction.

Pulm Pharmacol Ther 2018 Dec 21;53:39-51. Epub 2018 Sep 21.

Pharmacotherapeutics Unit, Department of Medicine, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Selangor, Malaysia. Electronic address:

Toluene diisocyanate (TDI) is a major cause of chemical-induced occupational asthma, which contributes about 15% of global asthma burden. Resistance and compounded side effects associated with the use of corticosteroid in asthma necessitate the search for alternative drugs. Andrographolide (AGP), a naturally occurring diterpene lactone is known to exhibit various bioactivities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2018.09.008DOI Listing
December 2018
1 Read

Impact of doxofylline compared to theophylline in asthma: A pooled analysis of functional and clinical outcomes from two multicentre, double-blind, randomized studies (DOROTHEO 1 and DOROTHEO 2).

Pulm Pharmacol Ther 2018 Dec 13;53:20-26. Epub 2018 Sep 13.

Department of Experimental Medicine and Surgery, University of Rome "Tor Vergata", Rome, Italy. Electronic address:

This pooled analysis of double-blind, randomized, placebo-controlled trials aimed to investigate the impact of DOxofylline compaRed tO THEOphylline (DOROTHEO 1 and DOROTHEO 2 studies) on functional and clinical outcomes in asthma. Asthmatic patients ≥16 years of age with forced expiratory volume in 1 s (FEV) ≥50% and <80% and with ≥15% post-bronchodilator increase in FEV were randomized in a 1:1:1:1 ratio in DOROTHEO 1 to receive doxofylline 200 mg, doxofylline 400 mg, theophylline 250 mg, or placebo; in DOROTHEO 2 patients were randomized in a 1:1:1 ratio to receive doxofylline 400 mg, theophylline 250 mg, or placebo. All double-blind treatments were taken orally with immediate release formulations and three times daily. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10945539183018
Publisher Site
http://dx.doi.org/10.1016/j.pupt.2018.09.007DOI Listing
December 2018
23 Reads

Pharmacokinetics and safety of a single dose of the novel LAMA/LABA fixed-dose combination of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler, formulated using co-suspension delivery technology, in Japanese healthy subjects.

Pulm Pharmacol Ther 2018 Dec 13;53:33-38. Epub 2018 Sep 13.

AstraZeneca, One MedImmune Way, Gaithersburg, MD, 20878, USA. Electronic address:

Background: Chronic obstructive pulmonary disease (COPD) causes significant mortality in Japan. GFF MDI is a long-acting muscarinic antagonist/long-acting β-agonist fixed-dose combination of glycopyrronium (GP) and formoterol fumarate dihydrate (FF), delivered by a metered dose inhaler (MDI) using co-suspension delivery technology, for the long-term maintenance treatment of COPD.

Methods: This randomized, Phase I, single-dose, four-treatment, four-period, crossover study (NCT02196714) examined the pharmacokinetic (PK) and safety profile of two doses of GFF MDI (28. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2018.09.005DOI Listing
December 2018
4 Reads

Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: Results of a single-centre observational study.

Pulm Pharmacol Ther 2018 Dec 11;53:1-5. Epub 2018 Sep 11.

Department of Medical and Surgical Sciences, Section of Respiratory Diseases, University "Magna Græcia" of Catanzaro, Italy. Electronic address:

Mepolizumab is a humanized monoclonal antibody which targets interleukin-5 (IL-5) and is nowadays available in many countries for add-on biological therapy of severe eosinophilic asthma. Although the approval of mepolizumab use in clinical practice has been made possible by several successful pre-marketing controlled trials, so far only a very few studies have been performed in a real-life setting. Within such a context, our present observational investigation refers to 14 patients with refractory eosinophilic asthma, currently treated with mepolizumab at the Respiratory Unit of "Magna Græcia" University Hospital located in Catanzaro, Italy, whose anti-IL-5 treatment began between June 2017 and January 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2018.09.006DOI Listing
December 2018
5 Reads

Differential regulation of cytokine and chemokine expression by MK2 and MK3 in airway smooth muscle cells.

Pulm Pharmacol Ther 2018 Dec 8;53:12-19. Epub 2018 Sep 8.

University of Nevada School of Medicine, Department of Pharmacology, Reno, NV, 89557, USA. Electronic address:

Background: Airway smooth muscle (ASM) contributes to local inflammation and plays an immunomodulatory role in airway diseases. This is partially regulated by p38 mitogen-activated protein kinase (MAPK), which further activates two closely related isoforms of the MAPK-activated protein kinases (MKs), MK2 and MK3. The MKs have similar substrate specificities but less is known about differences in their functional responses. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2018.09.004DOI Listing
December 2018
2 Reads

Development of a novel digital breath-activated inhaler: Initial particle size characterization and clinical testing.

Pulm Pharmacol Ther 2018 Dec 7;53:27-32. Epub 2018 Sep 7.

ARSM Research, Hickory, NC, USA.

Background: Delivery of inhaled respiratory medications have been associated with variable delivery of drug due to errors in device operations and have not been designed to monitor true delivery of medication. A fully digital breath-activated inhaled (DBAI) delivery platform has been developed with integrated firmware and software to address these limitations.

Methods: the device was designed to produce similar aerosol particle output to a marketed albuterol MDI and to the albuterol/ipratropium combination in a soft mist inhaler (SMI). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2018.08.007DOI Listing
December 2018
2 Reads

Pharmacologic targeting of the ATX/LPA axis attenuates bleomycin-induced pulmonary fibrosis.

Pulm Pharmacol Ther 2018 10 7;52:32-40. Epub 2018 Sep 7.

Division of Immunology, Biomedical Sciences Research Center Alexander Fleming, Athens, Greece. Electronic address:

Idiopathic pulmonary fibrosis (IPF) is a chronic fibrosing lung disease with a dismal prognosis and a largely unknown etiology. Autotaxin (ATX) is a secreted lysophospholipase D, largely responsible for extracellular production of lysophosphatidic acid (LPA), a bioactive phospholipid. LPA has numerous effects in most cell types, signaling through at least 6 receptors (LPAR) exhibiting wide spread distribution and overlapping specificities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2018.08.003DOI Listing
October 2018
2 Reads

Comorbidities of IPF: How do they impact on prognosis.

Pulm Pharmacol Ther 2018 Dec 5;53:6-11. Epub 2018 Sep 5.

Regional Referral Centre for Rare Lung Diseases, A.O.U. Policlinico-Vittorio Emanuele, University of Catania, Catania, Italy. Electronic address:

Idiopathic Pulmonary Fibrosis (IPF) is a severe parenchymal lung disease characterized by an intense deposition of collagen in the interstitial spaces. The introduction of anti-fibrotic drugs increased patients' life expectancy highlighting the role of comorbidities in patients' management and prognosis. IPF is frequently associated with other diseases mainly because of its onset during middle age and sometimes because of the presence of common pathogenic pathways such as in the case of lung cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2018.09.003DOI Listing
December 2018
9 Reads

Pharmacological approach and adherence to treatment recommendations in frequently and non-frequently exacerbating COPD patients from Italy: MISTRAL - The prospective cohort, observational study.

Pulm Pharmacol Ther 2018 Dec 5;53:68-77. Epub 2018 Sep 5.

Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Electronic address:

Background: Several documents and guidelines provide recommendations for effective management of COPD patients. However, there is often a significant imbalance between recommended treatment of COPD patients and the actual care provided both in primary care and specialty setting. This imbalance could result in a significant negative impact on patients' health status and quality of life, leading to increased hospitalisations and health resource utilisation in COPD patients METHODS: MISTRAL was an observational, longitudinal, prospective cohort study, designed to assess the overall pharmacological approach of COPD in routine clinical practice in Italy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2018.09.001DOI Listing
December 2018
11 Reads

Salvianolic acid B as an anti-emphysema agent II: In vivo reversal activities in two rat models of emphysema.

Pulm Pharmacol Ther 2018 Dec 5;53:52-60. Epub 2018 Sep 5.

Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University, 410 N. 12th Street, P. O. Box 980533, Richmond, VA, 23298, USA. Electronic address:

Emphysema progressively destroys alveolar structures, leading to disability and death, yet remains irreversible and incurable to date. Impaired vascular endothelial growth factor (VEGF) signaling is an emerging pathogenic mechanism, thereby proposing a hypothesis that VEGF stimulation/elevation enables recovery from alveolar structural destruction and loss of emphysema. Our previous in vitro study identified that salvianolic acid B (Sal-B), a polyphenol of traditional Chinese herbal danshen, stimulated lung cell proliferation and migration, and protected against induced lung cell death, by virtue of signal transducer and activator of transcription 3 (STAT3) activation and VEGF stimulation/elevation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2018.09.002DOI Listing
December 2018
5 Reads

Asthma COPD overlap: Impact of associated comorbidities.

Pulm Pharmacol Ther 2018 10 30;52:27-31. Epub 2018 Aug 30.

Section of Pulmonary, Critical Care and Sleep Medicine, Baylor College of Medicine, Houston, TX, USA. Electronic address:

Asthma and chronic obstructive pulmonary disease (COPD) are common chronic pulmonary conditions worldwide which often coexist. Patients with asthma COPD overlap (ACO) may have worse outcomes than those with either disease alone, for example, more respiratory symptoms and frequent exacerbations, and worse lung function. Additionally, there is a growing interest in factors that affect the disease including comorbid conditions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2018.08.006DOI Listing
October 2018
2 Reads

A proposed scheme to cope with comorbidities in asthma.

Pulm Pharmacol Ther 2018 10 25;52:41-51. Epub 2018 Aug 25.

ProAR - Federal University of Bahia School of Medicine, Brazil.

The prevalence of non-communicable chronic diseases has been on the rise and the co-occurrence of morbidities is becoming more common. Multimorbidities are found more frequently among women, those with a history of mental disorders, lower level of schooling, and unfavorable socioeconomic condition. Physical inactivity, smoking and obesity are also associated with multimorbidities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2018.08.005DOI Listing
October 2018
3 Reads

Protective role of glucocorticosteroid prior to endotoxin exposure in cultured neonatal type II alveolar epithelial cells.

Pulm Pharmacol Ther 2018 10 18;52:18-26. Epub 2018 Aug 18.

Laboratory of Pediatric Respiratory and Intensive Care Medicine, Department of Neonatology, Children's Hospital of Fudan University, Shanghai, China. Electronic address:

Background: Dexamethasone (DEX) is widely used for antenatal lung maturation and has been investigated to prevent premature lung injury by inhibiting postnatal inflammation. Its pharmacological mechanisms in the treatment of bacterial infection-induced injury of neonatal lung parenchymal cells remain to be clarified. We hypothesized that DEX pretreatment may attenuate endotoxin-induced growth suppression and regulate cytokine mRNA expression in cultured neonatal type II alveolar epithelial cells (AEC-II). Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10945539183008
Publisher Site
http://dx.doi.org/10.1016/j.pupt.2018.08.004DOI Listing
October 2018
5 Reads
2.940 Impact Factor

Effect of long-acting β-agonists olodaterol and formoterol on heart rate and blood pressure in chronic obstructive pulmonary disease patients.

Pulm Pharmacol Ther 2018 10 2;52:1-6. Epub 2018 Aug 2.

Department of Medicine, Pulmonary and Critical Care Medicine, Philipps University of Marburg, Marburg, Germany.

Background: Cardiovascular comorbidities are common in chronic obstructive pulmonary disease (COPD), and elevated heart rate reflects increased cardiovascular risk over time, which is associated with unfavourable neurohumoral activation. Long-acting β-agonists (LABAs) are established treatments in COPD, but potentially increase heart rate. We report a post hoc pooled analysis of the effect of olodaterol (5 or 10 μg) or formoterol (12 μg) on heart rate and blood pressure (BP) in Global Initiative for Chronic Obstructive Lung Disease Stage 2-4 COPD patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2018.08.002DOI Listing
October 2018
3 Reads

Effect of a spacer on total systemic and lung bioavailability in healthy volunteers and in vitro performance of the Symbicort (budesonide/formoterol) pressurized metered dose inhaler.

Pulm Pharmacol Ther 2018 10 2;52:7-17. Epub 2018 Aug 2.

AstraZeneca, Pepparedsleden 1, 431 50, Mölndal, Gothenburg, Sweden. Electronic address:

Introduction: Many patients with chronic obstructive pulmonary disease or asthma experience difficulties in coordinating inhalation with pressurized metered-dose inhaler (pMDI) actuation. The use of a spacer device can improve drug delivery in these patients. The aim of this study was to establish the relative bioavailability of single doses of Symbicort (budesonide/formoterol) pMDI 160/4. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2018.08.001DOI Listing
October 2018
5 Reads

Use of animal models in IPF research.

Pulm Pharmacol Ther 2018 08 5;51:73-78. Epub 2018 Jul 5.

Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, King's College London, London, SE1 9NH, UK.

Idiopathic pulmonary fibrosis (IPF) is a fatal interstitial lung disease with a poor prognosis and limited treatment options. Many compounds have shown efficacy in preclinical models of this condition, but only pirfenidone and nintedanib have been approved for clinical use. It is widely accepted that the current animal models of IPF need to be improved and in this review we have critically evaluated the current state of play of preclinical models of IPF and discuss the challenges facing this field. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2018.07.002DOI Listing
August 2018
2 Reads

Is aging a "comorbidity" of asthma?

Pulm Pharmacol Ther 2018 10 4;52:52-56. Epub 2018 Jul 4.

Division of Pulmonary, Critical Care, & Sleep Medicine Icahn School of Medicine at Mount Sinai, 1468 Madison Avenue, Annenberg Building 5th Floor, Room 5-20, New York, NY, 10029, USA. Electronic address:

The aging population is growing at an unparalleled rate. Asthma is common in the elderly (age over 65 years) and can be more severe with little chance for remission. Asthma in older individuals is often under-diagnosed, misdiagnosed and frequently under-treated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2018.06.005DOI Listing
October 2018
27 Reads

Hair analysis to monitor adherence to prescribed chronic inhaler drug therapy in patients with asthma or COPD.

Pulm Pharmacol Ther 2018 08 4;51:59-64. Epub 2018 Jul 4.

GSK, Stockley Park West, Uxbridge, Middlesex, UK.

Background: Poor adherence to inhaled drug therapy in individuals with asthma and/or chronic obstructive pulmonary disease (COPD) may be associated with suboptimal therapeutic outcomes. Measurement of drug residues in hair samples has been employed to assess oral medication use over time. Here, we test the feasibility of analyzing hair samples from patients with asthma and/or COPD for assessing adherence to prescribed inhaled medication. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2018.07.001DOI Listing
August 2018
4 Reads

The pharmacological treatment of chronic comorbidities in COPD: mind the gap!

Pulm Pharmacol Ther 2018 08 9;51:48-58. Epub 2018 Jul 9.

Internal Medicine and Geriatrics Area, University Campus Bio-Medico of Rome, Italy. Electronic address:

Background: Chronic obstructive pulmonary disease (COPD) is commonly associated with other chronic diseases, which poses several diagnostic and therapeutic problems. Indeed, important comorbidities frequently remain unrecognized and, then, untreated, whereas respiratory drugs may have non respiratory side effects, and selected non respiratory drugs may variably affect the respiratory function.

Objective: to describe: how COPD affects the presentation and contributes to the diagnostic challenges of its most common comorbidities; how coexisting COPD impacts the therapeutic approach to selected comorbidities and viceversa. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2018.06.004DOI Listing
August 2018
4 Reads